Haemonetics (HAE) Stock Forecast & Price Target

Haemonetics Corp has demonstrated significant growth potential, particularly within its plasma and hospital segments, highlighted by a notable 27% increase in its hemostasis management business in the U.S. Furthermore, the plasma segment has achieved double-digit growth, surpassing market expectations, primarily driven by market share gains with large customers and improved pricing following updates to its Persona and Express Plus products. These factors collectively underline a positive outlook for Haemonetics, indicating strong demand for its disposable blood component collection and processing solutions.

Haemonetics Corp's financial outlook is negatively impacted by its reported 21.7% decline in revenue, which has been attributed to divestiture activities, despite achieving 4.4% organic growth. Looking ahead, the company anticipates a total reported revenue decline of 3% to 6% for FY/26, which underscores concerns about ongoing challenges in sustaining growth amidst competition, especially in the blood center segment. Additionally, while the guidance reflects expectations of organic growth and stable margins, the potential drop in total revenue casts doubt on the company's ability to maintain profitability in the face of external pressures.